A Randomized Controlled Trial of Nonfasting vs Fasting Before Interventional Coronary Procedures: The TONIC Trial.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 24 01 2024
revised: 11 03 2024
accepted: 26 03 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 29 5 2024
Statut: ppublish

Résumé

Fasting before coronary procedures is currently recommended to reduce complications despite the lack of scientific evidence. The TONIC (Comparison Between Fasting and No Fasting Before Interventional Coronary Intervention on the Occurrence of Adverse Events) noninferiority trial investigated the safety and comfort of a nonfasting strategy (ad libitum food and drinks) vs traditional fasting (>6 hours for solid food and liquids) before coronary procedures. In this monocentric, prospective, single-blind randomized controlled trial, 739 patients undergoing coronary procedures were included and randomized to a fasting or a nonfasting strategy. Emergency procedures were excluded. The primary endpoint was a composite of vasovagal reaction, hypoglycemia (defined by blood sugar ≤0.7 g/L), and isolated nausea and/or vomiting. Noninferiority margin was 4%. Secondary endpoints were contrast-induced nephropathy and patients' satisfaction. Among the 739 procedures (697 elective and 42 semiurgent), 517 angiographies, and 222 angioplasties (including complex and high-risk procedures) were performed. The primary endpoint occurred in 30 of 365 nonfasting patients (8.2%) vs 37 of 374 fasting patients (9.9%), demonstrating noninferiority (absolute between-group difference, -1.7%; 1-sided 95% CI upper limit: 1.8%). No food-related adverse event occurred, and contrast-related acute kidney injuries were similar between groups. Overall, procedure satisfaction and perceived pain were similar in both groups, but nonfasting patients reported less hunger and thirst (P < 0.01). In case of redo coronary procedures, most patients (79%) would choose a nonfasting strategy. The TONIC randomized trial demonstrates the noninferiority of a nonfasting strategy to the usual fasting strategy for coronary procedures regarding safety, while improving patients' comfort.

Sections du résumé

BACKGROUND BACKGROUND
Fasting before coronary procedures is currently recommended to reduce complications despite the lack of scientific evidence.
OBJECTIVES OBJECTIVE
The TONIC (Comparison Between Fasting and No Fasting Before Interventional Coronary Intervention on the Occurrence of Adverse Events) noninferiority trial investigated the safety and comfort of a nonfasting strategy (ad libitum food and drinks) vs traditional fasting (>6 hours for solid food and liquids) before coronary procedures.
METHODS METHODS
In this monocentric, prospective, single-blind randomized controlled trial, 739 patients undergoing coronary procedures were included and randomized to a fasting or a nonfasting strategy. Emergency procedures were excluded. The primary endpoint was a composite of vasovagal reaction, hypoglycemia (defined by blood sugar ≤0.7 g/L), and isolated nausea and/or vomiting. Noninferiority margin was 4%. Secondary endpoints were contrast-induced nephropathy and patients' satisfaction.
RESULTS RESULTS
Among the 739 procedures (697 elective and 42 semiurgent), 517 angiographies, and 222 angioplasties (including complex and high-risk procedures) were performed. The primary endpoint occurred in 30 of 365 nonfasting patients (8.2%) vs 37 of 374 fasting patients (9.9%), demonstrating noninferiority (absolute between-group difference, -1.7%; 1-sided 95% CI upper limit: 1.8%). No food-related adverse event occurred, and contrast-related acute kidney injuries were similar between groups. Overall, procedure satisfaction and perceived pain were similar in both groups, but nonfasting patients reported less hunger and thirst (P < 0.01). In case of redo coronary procedures, most patients (79%) would choose a nonfasting strategy.
CONCLUSIONS CONCLUSIONS
The TONIC randomized trial demonstrates the noninferiority of a nonfasting strategy to the usual fasting strategy for coronary procedures regarding safety, while improving patients' comfort.

Identifiants

pubmed: 38811102
pii: S1936-8798(24)00649-6
doi: 10.1016/j.jcin.2024.03.033
pii:
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article Comparative Study Equivalence Trial Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1200-1210

Informations de copyright

Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures The study’s sponsor was Assistance Publique–Hôpitaux de Paris (Délégation à la Recherche Clinique et à l'Innovation). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Madjid Boukantar (M)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France. Electronic address: madjid.boukantar@aphp.fr.

Paul-Matthieu Chiaroni (PM)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Romain Gallet (R)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Patrick Zamora (P)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Tony Truong (T)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Andrea Mangiameli (A)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Laura Rostain (L)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Anne-Sophie Tuffreau-Martin (AS)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Pierre-André Natella (PA)

Clinical Research Unit, Henri Mondor Hospital, Créteil, France.

Nadia Oubaya (N)

University Paris Est Créteil, INSERM, IMRB, Créteil, France; AP-HP, Hôpitaux Henri-Mondor, Department of Public Health, Creteil, France.

Emmanuel Teiger (E)

Interventional Cardiology, Henri Mondor Hospital, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH